---
id: ahs-migraine-2021
title: "American Headache Society Consensus Statement: Update on Integrating New Migraine Treatments into Clinical Practice"
short_title: "AHS Migraine Treatment 2021"

organization: American Headache Society
collaborators: null
country: US
url: https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.14153
doi: 10.1111/head.14153
pmid: 34160823
open_access: false

specialty: neurology
guideline_type: consensus
evidence_system: other
conditions:
  - migraine
  - chronic migraine
  - episodic migraine
tags:
  - CGRP inhibitors
  - triptans
  - gepants
  - preventive therapy
  - acute treatment
  - erenumab
  - fremanezumab

publication_date: 2021-06-23
previous_version_date: 2019-01-01
status: current
supersedes: ahs-migraine-2019
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-21
---

## Scope

Updated guidance on integrating new acute and preventive migraine treatments (CGRP-targeted therapies, gepants, ditans) into clinical practice for adults.

## Notes

Incorporates research findings, expert consensus, and patient perspectives. Recommends preventive therapy for patients with ≥4 migraine days/month or ≥2 days/month with substantial disability.
